Justices reject holding generic pharmaceutical manufacturers liable for decisions of pharmacists about prescribing their products

The Supreme Court unanimously ruled that generic drug manufacturer Hikma Pharmaceuticals cannot be held liable for patent infringements by branded drugmaker Amarin Pharma, rejecting claims that Hikma's labeling, press releases, and website statements actively induced infringement. The case centered on whether Hikma's generic version of Vascepa, used interchangeably with Amarin's patented drug for cardiovascular and hypertriglyceridemia treatments, could be blamed for doctors and pharmacists using the generic for patented purposes.